Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
The first wave of biotechs developing drugs that employ targeted protein degradation target disease-causing proteins inside the cell. Biotech startup Avilar Therapeutics, formed by RA Capital Management and led by CEO Dan Grau, is targeting proteins outside of the cell and it’s out of stealth backed by $60 million.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biotech startup Janux Therapeutics has a technology that selectively and safely directs T cells to strike cancer cells and an R&D partnership with Merck. Now it has $125 million in Series B financing as it joins the chase to bring these T cell engager drugs to solid tumors.
RA Capital led Ventus Therapeutics' Series B financing, which the startup will use to develop its pipeline of medicines for “undruggable” disease targets. CEO Marcelo Bigal said the cash also gives Ventus the flexibility to consider an IPO.
Massachusetts-based Be Biopharma will use the proceeds to build a team as it seeks to develop B-cell therapies for a variety of diseases.
Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company is developing tumor-infiltrating lymphocyte therapies that target patient-specific neoantigens. It plans to use the money to fund Phase I/IIa studies in solid tumors.
The South San Francisco company intends to use the funding to launch its pivotal trial for its blood-based colorectal cancer screening and submit its test for parallel review for CMS coverage.
The firm said the new round increased its private deal capacity to nearly $1 billion and total assets under management to around $2.5 billion.
Many proteins known to play roles in cancers are considered "undruggable" because they lack pockets for drugs to bind to. Amgen drew attention at ASCO with data on a drug targeting a KRAS mutation, generally considered not amenable to pharmaceutical therapy.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The company hopes the funding will move it toward the clinic. Active clinical programs of gene therapies in Parkinson's include efforts by Voyager Therapeutics and a university in Japan.
5AM Ventures and RA Capital Management led the round. The company is developing hematopoietic stem cells engineered to be protected from targeted immunotherapies.
The new company is headquartered in San Francisco, with R&D in Israel and has launched a Phase I study of BIO89-100, formerly TEV-47948.
The company plans to use the funding to advance LYR-210 into a Phase II clinical trial and also explore its development platform in other ENT diseases.
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.